Article
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jun 2018
Morita Kiyomi, Kantarjian Hagop M, Wang Feng, Yan Yuanqing, Bueso-Ramos Carlos, Sasaki Koji, Issa Ghayas C, Wang Sa, Jorgensen Jeffrey, Song Xingzhi, Zhang Jianhua, Tippen Samantha, Thornton Rebecca, Coyle Marcus, Little Latasha, Gumbs Curtis, Pemmaraju Naveen, Daver Naval, DiNardo Courtney D, Konopleva Marina, Andreeff Michael, Ravandi Farhad, Cortes Jorge E, Kadia Tapan, Jabbour Elias, Garcia-Manero Guillermo, Patel Keyur P, Futreal P Andrew, Takahashi Koichi
Abstract excerpt
Purpose The aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated patients with AML who received intensive induction chemotherapy and attained morphologic complete remission (CR) at day 30 were studied. Pretreatment and CR bone...
Topics
Join the communities discussing this publication.